The use of 15-methylated derivative of prostaglandin F2a for the therapeutic termination of pregnancy and management of late fetal death.
The administration of 15-me-PGF 2a for the therapeutic termination of pregnancy and management of intrauterine death of the embryo during the second and third trimester of pregnancy was studied in 92 patients. Of these, 52 came because of intrauterine death with an average gestational age of 28.7 weeks while the rest came for therapeutic termination of pregnancy with an average gestational age of 21 weeks. Successful abortion was achieved in 90 patients. The mean abortion induction time was 7.3 hours for patients with intrauterine death and 12.6 hours for the patients who came for therapeutic termination. The results and complications of the intramuscular administration of the 15-me-PFG2a are analysed in the present work.
D000028:Abortion, Induced / Q000379:methods*; D000032:Abortion, Therapeutic / Q000379:methods; D000293:Adolescent; D000328:Adult; D002260:Carboprost; D004305:Dose-Response Relationship, Drug; D005260:Female; D005313:Fetal Death; D006801:Humans; D007273:Injections, Intramuscular; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D011263:Pregnancy Trimester, Third; D011461:Prostaglandins F, Synthetic
D011461:Prostaglandins F, Synthetic; D002260:Carboprost